Classical epidemiological studies have identified populations and families at increased cancer risk. Molecular epidemiology has a more ambitious goal, i.e. the identification of individuals at high cancer risk in these cancer-prone populations and families. Achieving this goal is challenging both current molecular technologies and epidemiological designs, and exposing bioethical dilemmas.
The two facets of molecular epidemiology of human cancer risk are assessment of carcinogen exposure and inherited or acquired host cancer-susceptibility factors (reviewed in Harris, 1991; Perera and Santella, 1993) . The interaction between these two facets determines an individual's cancer risk. This paradigm can also improve cancer risk assessment (Figure 1 ). When combined with carcinogen bioassays in laboratory animals and classical epidemiology molecular epidemiology can contribute to the four traditional aspects of cancer risk assessment: hazard identification, dose -response assessment, exposure assessment and risk characterisation. Improved cancer risk assessment has broad public health and economic implications (National Research Council, 1994) .
Weighty bioethical consequences follow the identification of high-risk individuals (Li et al., 1992) . The bioethical issues include: autonomy, privacy, justice and equity ( Figure 1 ). One can argue that the knowledge of one's risk can be beneficial. However, more encompassing bioethical issues arise, such as an individual's responsibility to family members and psychosocial concerns regarding the genetic testing of children (Li et al., 1992) . Therefore, the uncertainty of the current individual risk assessments and the limited availability of genetic counselling services dictate caution and, many argue, the restriction of genetic testing to those conditions amenable to preventative or therapeutic intervention.
This lecture will discuss cancer susceptibility genes as inherited host factors and then focus on the mutational spectrum of the p53 tumour-suppressor gene and the testing of hypotheses generated by the analysis of this gene. The discussion of the p53 gene will complement the excellent 1993 Walter Hubert Lecture presented by Arnold Levine .
Correspondence: CC Harris Received 27 July 1995; accepted 18 August 1995 The investigation of rare cancer-prone families has led to the identification of germline mutations in genes that are frequently somatically mutated in sporadic cancers. Examples of these syndromes are listed in Table I . The altered genes encode proteins that perform diverse cellular processes, including transcription, cell cycle control, xenobiotic metabolism and DNA repair. The increased cancer risk of an individual carrying one of these germline mutations can be extraordinarily high, i.e. more than 1000-fold in xeroderma pigmentosum (complementation groups A-G) (Figure 2 ). However, high-risk inherited conditions are rare in the general population and number only a few cases in 105 live births. More common inherited cancer-susceptibility conditions, e.g. deficiencies in the N-acetyltransferase (NAT) genes or glutathione S-transferase genes, may contribute a more substantial attributable risk in a carcinogen-exposed population.
The recently identified cancer-susceptibility genes involved in breast-ovarian cancer (BRCAI) (Lane and Benchimol., 1990; Dittmer et al., 1993; Hsiao et al., 1994) . The p53 gene was initially classified as an oncogene until it was discovered in the late 1980s that the cDNAs cloned from murine and human tumour cells contained missense mutations; it was correctly classified when a true wild-type p53 gene construct suppressed the growth of tumour cells (Eliyahu et al., 1989; Finlay et al., 1989; Baker et al., 1990; Diller et al., 1990; Mercer et al., 1990; Chen et al., 1991; Cariello et al., 1994) . This Dr Jekyll and Mr Hyde duality may be one explanation of the remarkable frequency of p53 mutations in human cancer. The p53 gene is well suited to mutational spectrum analysis for several reasons. First, since p53 mutations are common in many human cancers, a sizable database of about 5000 entries has accrued, the analysis of which can yield statistically valid conclusions . The modest size of the p53 gene (11 exons, 393 amino acids) permits study of the entire coding region, and it is highly conserved in vertebrates, allowing extrapolation of data from animal models (Soussi et al., 1990) . Point mutations that alter p53 function are distributed over a large region of the molecule, especially in the hydrophobic midportion (Hollstein et al., 1991; Levine et al., 1991; Greenblatt et al., 1994) , where many base substitutions alter p53 conformation and sequence-specific transactivation activity; thus, correlations between distinct mutants and functional changes are possible. Frameshift and nonsense mutations that truncate the protein can be located outside of these regions, so evaluation of the entire DNA sequence yields relevant data. This situation differs from the ras oncogenes whose transforming mutations occur primarily in three codons, a few sequence motifs and a critical functional domain (Park and Vande Woude., 1989) . The diversity of p53 mutational events permits more extensive inferences regarding mechanisms of DNA damage and mutation.
Molecular archaeology of p53 mutations
Mutations can arise by either endogenous mutagenic mechanisms or exogenous mutagenic agents and are archived in the spectrum of p53 mutations found in human cancer (Hollstein et al., 1991; Levine et al., 1991; Harris, 1993; Greenblatt et al., 1994; Soussi et al., 1994 more identical bases or at repeats of 2-to 8-base pair DNA motifs, either in tandem or separated by a short intervening sequence. Several mechanisms are probably involved (Ripley, 1990 Krawczak and Cooper, 1991) . More lengthy runs and sequence repeats are more likely to generate frameshift mutations. The detection of errors in replication of reporter genes has helped quantify this phenomenon (Kunkel, 1993) . The deletions and insertions in the p53 gene found in human tumours also may be biologically selected from the broad array of such mutations occurring in human cells. When compared with the distribution of missense mutations, these types of mutations occur more frequently in exons 2-4 (54%) and 9-11 (77%) than in exons 5-8 (20%) (Figure 4 ). al., 1991; Nguyen et al., 1992) so that the production of nitric oxide by inducible nitric oxide synthase could contribute to this endogenous mechanism of mutagenesis.
The missense mutations in the p53 gene are non-random. Five of the six mutational hotspots in the p53 gene occur at CpG dinucleotides in codons encoding the basic amino acid, arginine ( Figure 6 ). These mutational hotspots are at sites that are essential for maintaining the interface between the p53 protein and its DNA consensus site responsible for DNA binding and transcriptional activity. This structure -function relationship became readily apparent when the crystal structure of the p53 protein was compared with the p53 mutation spectrum (Cho et al., 1994; Prives, 1994 al., 1991; Ziegler et al., 1994) . The high frequency of CC to TT transitions in the nontranscribed DNA strand is a reflection of strand-specific repair of the p53 gene (Evans et al., 1993) . Since patients with xeroderma pigmentosum group C have a severe deficiency in nucleotide excision repair of the non-transcribed strand of DNA, one would expect a higher frequency of CC to TT transitions with a coding strand bias in skin carcinomas from these individuals (Evans et al., 1993) . This prediction has proven to be correct (Figure 7) (Dumaz et al., 1994) . Mutations of dipyrimidine sites in skin carcinomas also show a non-random distribution among sites within the p53 gene. Recent studies have shown that rates of cyclobutane dimer repair very among codons within p53 (Tornaletti and Pfeifer, 1994 observed in hepatocellular carcinoma from Asia, Africa and North America (Figure 8 ). The mutation load of 249ser mutant cells in non-tumorous liver also is positively correlated with dietary aflatoxin B1 (AFB1) exposure (Aguilar et al., 1994 (Ponchel et al., 1994) . The 249Ser mutant p53 also is more effective than other p53 mutants (143Aa, 175His, 248TrP and 282His) in inhibiting wild-type p53 transcriptional transactivation activity in human liver cells (Figure 9 ). One hypothesis concerning generation of liver cancers with 249ler mutation is: (a) aflatoxin B1 is metabolically activated to form the promutagenic N7dG adduct; and (b) enhanced cell proliferation due to chronic active viral hepatitis allows both fixation of the G:C to T:A transversion in codon 249 of the p53 gene and selective clonal expansion of the cells containing this mutant p53 gene. In addition to producing chronic active hepatitis, HBV also has other important pathobiological effects. For example, hepatitis B viral gene products may form complexes with cellular transcription factors, e.g. ATF2 (Maguire et al., 1991) , up-regulate transcription of cellular and viral genes (Twu and Schlozmer, 1987; Spandau and Lee, 1988 including DNA repair and apoptosis may be another consequence of cellular protein-HBV oncoprotein complex formation. Since the HBVX gene is frequently integrated and expressed in human hepatocellular carcinomas from high-risk geographic areas (Unsal et al., 1994; Paterlini et al., 1995) , we have focused our attention on the X protein, which binds to p53 (Feitelson et al., 1993; Wang et al., 1994; Ueda et al., 1995) and inhibits its sequence-specific DNA binding and transcriptional activity (Wang et al., 1994) . HBV protein also the scientific basis of risk assessment continues to be, and should continue to be, actively investigated (National Research Council, 1994) .
The association of a suspected carcinogenic exposure and cancer risk can be studied in populations with classic epidemiological techniques. However, these techniques are not applicable to the assessment of risk in individuals. Molecular epidemiology, in contrast, is a field that integrates molecular biology, in vitro and in vivo laboratory models, biochemistry and epidemiology to infer individual cancer risk (reviewed in Harris, 1991; Shields and Harris, 1991; Perera and Santella, 1993) (Figure 1 ). Carcinogen-macromolecular adduct levels, and somatic cell mutations can be measured to determine the biologically effective dose of carcinogen. Molecular epidemiology also explores host cancer susceptibilities, such as carcinogen metabolic activation, DNA repair, endogenous mutation rates and inheritance of tumour-suppressor genes. Substantial interindividual variation for each of these biological end points has been shown -'1^-^0 %001 vJ I I 268 (Harris, 1991) (Figure 1 ).
